An interventional study of active tDCS and workbook in Major Depression, Pregnancy and Postpartum Depression, sponsored by Women's College Hospital. Recruiting at 2 sites in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Women's College Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 312 studies in Depressive Disorder, Major with a site in Canada — 66 open to participants now, 82 under way, 12 of them phase 3. Depressive Disorder, Major · Canada.
Among the 312 studies in Depressive Disorder, Major with a site in Canada, this one is the 92nd largest by planned enrollment of the 284 interventional ones that give a count, is one of 23 that started in 2021, is one of 132 with no phase, reaches primary completion later than 43 of the 81 other live ones, and was the 225th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →66 of the 312 studies in Depressive Disorder, Major with a site in Canada are open now. Recruiting first, the newest first:
The Royal's Institute of Mental Health Research · Sites in Canada
Ages 18–65
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
Lawson Research Institute of St. Joseph's · Sites in Canada
Ages 18+
Eli Lilly and Company · Sites in Canada, United States, Australia and 12 more countries
Ages 18–75
University of Toronto · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
312 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 45 · Phase 3 76 · Phase 4 28
First in 1999; this study’s year is marked. 23 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 156 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 284 interventional studies, 120 across the 27 observational. Of the 196 that completed or were terminated, 50 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 312 have an industry lead sponsor. The 10 most frequent:
Women's College Hospital is the lead sponsor of 87 studies on the registry; 16 are open to participants now.
Women's College Hospital has 3 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
24 of the studies in Depressive Disorder, Major with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07262008Phase 3Women's College HospitalSustained Mood Improvement With Laughing Gas Exposure | 2027-02-01 |
| NCT06891300Phase 3The Royal's Institute of Mental Health ResearchUnderstanding and Treating Suicidal Ideation With Ketamine | 2027-03 |
| NCT06963021Phase 3Neurocrine BiosciencesNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
| NCT05423275University of British ColumbiaLight and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study | 2026-12 |
| NCT06163625Unity Health TorontoThe Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 312 studies in Depressive Disorder, Major with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, sham-controlled trial to determine whether treatment with transcranial direct current stimulation (tDCS) is superior to a sham condition at reducing the symptoms of depression in pregnant people with moderate to severe depression. The study aims to enrol 156 participants across all sites. Data collection occurs at baseline, immediately after treatment, every 4 weeks during pregnancy and 4-, 12-, 26- and 52-weeks postpartum
Transcranial direct current stimulation (tDCS) is a brain stimulation technique for the treatment of depression that has great potential for filling the gap in treatment options for moderate and severe depression in pregnancy. Participants are randomized 1:1 to active tDCS treatment or sham control. After at least one in-person training session with the research team, participants take the tDCS device home and self-administer 30-minute treatments 5 times per week, for 3 weeks, for a total of 15 sessions. Rater-administered and self-report outcomes are collected weekly during the 3-week active treatment phase, every 4 weeks during pregnancy, and at 4-, 12-, 26- and 52-weeks postpartum. A mixed methods process evaluation is embedded into the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
2mA of direct current delivered to the dorsolateral prefrontal cortex for 30 minutes each, 5 times per week for 3 weeks, for a total of 15 sessions using the Soterix Medical tDCS mini-CT model 1601-LTE.
Device: active tDCS · Other: workbook
Sham stimulation where the current is turned off after 30 seconds in a slow ramp down, delivered to the dorsolateral prefrontal cortex for 30 minutes each, 5 times per week for 3 weeks, for a total of 15 sessions using the Soterix Medical tDCS mini-CT model 1601-LTE.
Other: workbook · Device: sham tDCS
2mA of direct current delivered in 15 sessions lasting 30 minutes each over 3 weeks
Self-directed depression in pregnancy workbook completed during each session to control the in-session brain state
Sham stimulation in which the current turns off after 30 seconds in a slow ramp down that mirrors sensory adaptation in ongoing stimulation, delivered in 15 sessions lasting 30 minutes each over 3 weeks
Depressive symptoms post treatment
Depressive symptoms are measured with the 10-item rater-administered Montgomery Asberg Depression Rating Scale (MADRS).The MADRS is a standard rater-administered measure with good reliability and validity in clinical populations; interviewers can achieve and maintain high levels of inter-rater reliability. Nine items are based upon patient report and one on rater observation. Items are rated on a 0-6 continuum (0=no abnormality, 6=severe; score range 0-60). A MADRS score of \<11 indicates remission. With 80% power, and a type 1 error rate of 0.05 we would require a sample size of 104 (52/group) to detect a statistically significant difference between tDCS and Sham on the primary outcome.
Time frame: End of Week 3 of treatment
Remission of depression
Measured with the 10-item rater-administered Montgomery Asberg Depression Rating Scale (MADRS).The MADRS is a standard rater-administered measure with good reliability and validity in clinical populations; interviewers can achieve and maintain high levels of inter-rater reliability. Nine items are based upon patient report and one on rater observation. Items are rated on a 0-6 continuum (0=no abnormality, 6=severe; score range 0-60). A MADRS score of \<11 indicates remission. With 80% power, and a type 1 error rate of 0.05 we would require a sample size of 124 (62/group) to detect a statistically significant difference between tDCS and Sham on this main secondary outcome.
Time frame: 4 weeks postpartum
Depressive symptoms
measured with the 10-item rater-administered Montgomery Asberg Depression Rating Scale (MADRS).The MADRS is a standard rater-administered measure with good reliability and validity in clinical populations; interviewers can achieve and maintain high levels of inter-rater reliability. Nine items are based upon patient report and one on rater observation. Items are rated on a 0-6 continuum (0=no abnormality, 6=severe; score range 0-60). A lower score indicates less severe symptoms.
Time frame: End of Week 1, and Week 2 of treatment, q4 weeks during pregnancy, and 4-, 12-, 26- and 52-weeks postpartum
Self-reported depressive symptoms
Depressive symptoms will be measured using the Edinburgh Postnatal Depressive Scale (EPDS), a self-report scale that has been validated for use in pregnancy and postpartum. EPDS scores range from 0 to 30. EPDS scores \>12 are predictive of a diagnosis of depression, with higher scores indicating more severe symptoms
Time frame: End of Week 1, Week 2 and Week 3 of treatment, q4 weeks during pregnancy (up to 28 weeks), and 4-, 12-, 26- and 52-weeks postpartum (up to 80 weeks)
Self-reported anxiety symptoms
Measured using the Generalized Anxiety Disorder-7 (GAD-7) scale which is a self-report scale with good discriminate validity in perinatal populations. GAD-7 scores range from 0 to 21, with higher scores indicating more severe symptoms
Time frame: End of Week 1, Week 2 and Week 3 of treatment, q4 weeks during pregnancy (up to 28 weeks), and 4-, 12-, 26- and 52-weeks postpartum (up to 80 weeks)
Maternal Quality of Life (QoL)
Measured using 12-Item Short Form Survey (SF-12), a 12-item measure often used to estimate quality-adjusted life year (QALY), a preference-based utility measure of health-related QoL as perceived by the patient and the gold standard measure of effectiveness recommended for economic evaluation. SF12 scores consist of Physical and Mental Component Summaries. Scores range from 0-100 with higher scores indicating better functioning
Time frame: End of Week 1, Week 2 and Week 3 of treatment, q4 weeks during pregnancy (up to 28 weeks), and 4-, 12-, 26- and 52-weeks postpartum (up to 80 weeks)
Health Service Use: Health System Costs
Calculated from participant self-report of medical costs such as hospitalization, visits with health professionals and medications
Time frame: End of Week 3 of treatment, q4 weeks during pregnancy (up to 28 weeks), and 4-, 12-, 26- and 52-weeks postpartum (up to 80 weeks)
Health Service Use: Productivity Loss
Calculated from participant self-report of activities and time commitment related to attending appointments and obtaining services, work absences of the patient and family members
Time frame: End of Week 3 of treatment, q4 weeks during pregnancy (up to 28 weeks), and 4-, 12-, 26- and 52-weeks postpartum (up to 80 weeks)
Health Service Use: Participant Cost
Calculated from participant self-report of costs related to attending appointments and obtaining services
Time frame: End of Week 3 of treatment, q4 weeks during pregnancy (up to 28 weeks), and 4-, 12-, 26- and 52-weeks postpartum (up to 80 weeks)
Dyadic Relationship
Relationship satisfaction measured using the Dyadic Consensus Subscale, a 13-item subscale of the 32-item Dyadic Adjustment Scale (DAS). This self-report measure of the extent of agreement between partners is valid for measuring overall dyadic adjustment. Higher scores indicate a higher degree of dyadic consensus
Time frame: End of Week 3 of treatment, q4 weeks during pregnancy (up to 28 weeks), and 4-, 12-, 26- and 52-weeks postpartum (up to 80 weeks)
Maternal Birth Outcomes
Self-reported pregnancy and birth complications querying indicators recommended by the Canadian Perinatal Surveillance System (CPSS)
Time frame: End of Week 1, Week 2 and Week 3 of treatment, q4 weeks during pregnancy (up to 28 weeks), and 4 weeks postpartum (up to 32 weeks)
Neonatal Birth Outcomes
Self-reported neonatal birth outcomes including medical conditions and complications querying indicators recommended by the Canadian Perinatal Surveillance System (CPSS)
Time frame: 4 weeks postpartum (up to 32 weeks)
Maternal Child Relationship
Parenting stress is measured by the Parenting Stress Index Short Form (PSI-SF) which is a 36-item measure consisting of 6 sub-scales: parental distress, dysfunction in the parent-child relations and difficult child. Scores range from 36 to 180. Higher scores indicate higher levels of parenting stress
Time frame: 4-, 12-, 26- and 52-weeks postpartum (up to 80 weeks)
Infant Temperament
Measured using the Infant Characteristics Questionnaire (ICQ). The ICQ is a 27-item questionnaire with each item coded 1-7. Higher scores indicate higher parental perceptions of difficult infant temperament
Time frame: 12 and 52 weeks postpartum (up to 80 weeks)
Child Development
Assessed using the Ages and Stages Questionnaire (ASQ-3), a 30-item instrument that screens for child development from 1 to 60 months
Time frame: 12 and 52 weeks postpartum (up to 80 weeks)
Concurrent Health Service Use
Self-reported concurrent mental health service use such as psychotherapy or antidepressant use that could confound treatment
Time frame: End of Week 1, Week 2 and Week 3 of treatment, q4 weeks during pregnancy (up to 28 weeks), and 4-, 12-, 26- and 52-weeks postpartum (up to 80 weeks)
Tolerability of Intervention
Assessed using the rater-administered Toronto Side Effects Scale which is an anti-depressant side effects scale
Time frame: End of Week 1, Week 2 and Week 3 of treatment
Stanford Expectancy Scale
Assesses participant expectations of treatment effectiveness
Time frame: Baseline
Integrity of Treatment Blindness Questionnaire
Participants report whether they believe they have received the treatment or the sham control.
Time frame: End of session 1, End of Week 3 of treatment
Started Nov 2021 (actual). Primary completion is estimated for Mar 2027, 64 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 64 months is above that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Women's College Hospital